Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1956 3
1957 2
1958 5
1960 2
1961 6
1962 16
1963 4
1964 4
1965 1
1966 3
1967 5
1968 8
1969 9
1970 7
1971 6
1972 6
1973 5
1974 6
1975 7
1976 14
1977 16
1978 23
1979 19
1980 19
1981 27
1982 28
1983 31
1984 29
1985 30
1986 32
1987 33
1988 45
1989 60
1990 58
1991 61
1992 61
1993 58
1994 74
1995 106
1996 117
1997 116
1998 110
1999 151
2000 199
2001 238
2002 239
2003 301
2004 408
2005 486
2006 515
2007 638
2008 710
2009 848
2010 1063
2011 1170
2012 1229
2013 1321
2014 1347
2015 1487
2016 1499
2017 1432
2018 1479
2019 1427
2020 1607
2021 1572
2022 1439
2023 1507
2024 1461
2025 114

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24,220 results

Results by year

Filters applied: . Clear all
Page 1
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.
Yun J, Lee SH, Kim SY, Jeong SY, Kim JH, Pyo KH, Park CW, Heo SG, Yun MR, Lim S, Lim SM, Hong MH, Kim HR, Thayu M, Curtin JC, Knoblauch RE, Lorenzi MV, Roshak A, Cho BC. Yun J, et al. Among authors: lee sh. Cancer Discov. 2020 Aug;10(8):1194-1209. doi: 10.1158/2159-8290.CD-20-0116. Epub 2020 May 15. Cancer Discov. 2020. PMID: 32414908 Clinical Trial.
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer.
Park S, Ock CY, Kim H, Pereira S, Park S, Ma M, Choi S, Kim S, Shin S, Aum BJ, Paeng K, Yoo D, Cha H, Park S, Suh KJ, Jung HA, Kim SH, Kim YJ, Sun JM, Chung JH, Ahn JS, Ahn MJ, Lee JS, Park K, Song SY, Bang YJ, Choi YL, Mok TS, Lee SH. Park S, et al. Among authors: lee sh. J Clin Oncol. 2022 Jun 10;40(17):1916-1928. doi: 10.1200/JCO.21.02010. Epub 2022 Mar 10. J Clin Oncol. 2022. PMID: 35271299 Free PMC article.
2024 KSoLA Consensus on Secondary Dyslipidemia.
Won H, Bae JH, Lim H, Kang M, Kim M, Lee SH; Clinical Practice Guidelines Committee, Korean Society of Lipid and Atherosclerosis (KSoLA). Won H, et al. Among authors: lee sh. J Lipid Atheroscler. 2024 Sep;13(3):215-231. doi: 10.12997/jla.2024.13.3.215. Epub 2024 Sep 4. J Lipid Atheroscler. 2024. PMID: 39355405 Free PMC article. Review.
24,220 results
You have reached the last available page of results. Please see the User Guide for more information.